Top IVF Devices and Consumables Companies

Global IVF Devices and Consumables Market size was valued at USD 3.33 Billion in 2024 and is poised to grow from USD 3.97 Billion in 2025 to USD 16.08 Billion by 2033, growing at a CAGR of 19.1% during the forecast period (2026–2033). 

The global IVF devices and consumables market is highly competitive, with key players focusing on technological advancements, product innovations, and strategic partnerships to maintain market share. CooperSurgical, Merck Group, Vitrolife, Ferring Pharmaceuticals, and Thermo Fisher Scientific are some of the major market players. Such companies are researching and developing more products, adding to their existing portfolios, and improving their supply chains to help them meet increasing demand for IVF treatments throughout the world. 'Cook Medical Inc. (USA) ', 'The Cooper Companies, Inc. (USA) ', 'CooperSurgical, Inc. (USA) – (The Cooper Companies, Inc.) ', 'Merck KGaA (Germany) ', 'EMD Serono, Inc. (USA) – (Merck KGaA) ', 'Thermo Fisher Scientific Inc. (USA) ', 'FUJIFILM Holdings Corporation (Japan) ', 'FUJIFILM Irvine Scientific Inc. (USA) – (FUJIFILM Holdings Corporation) ', 'Vitrolife AB (Sweden) ', 'Esco Lifesciences Group (Singapore) ', 'Genea Biomedx (Australia) ', 'Hamilton Thorne Ltd. (Canada) ', 'Memmert GmbH + Co. KG (Germany) ', 'Nidacon International AB (Sweden) ', 'Kitazato Corporation (Japan) ', 'BIOPSYBELL Srl (Italy) ', 'CCD Laboratory (France) ', 'Esco Medical (Singapore) – (Esco Lifesciences Group) ', 'Intermedics Ltd. (UK) ', 'INVO Bioscience Inc. (USA)'

The rising prevalence of infertility, influenced by factors such as delayed pregnancies, lifestyle changes, and environmental factors, is a major driver for the IVF devices and consumables market. There is an increased number of people and couple seeking fertility treatment, and relatedly, there is a growing demand for higher IVF technologies and consumables.

Shift Towards Personalized IVF Treatments: The demand for personalized IVF treatments is significantly growing as advancements in genetic screening and artificial intelligence (AI) improve the customization of IVF procedures. Fertility clinics have increasingly embraced the use of technology that offers tailoring of treatment to an individual's genetic profile, which improves success rates. This way, it improves the outcome of a patient, limits the possibility of multiple cycles, and thus leads to cost effectiveness. Personalized treatments are increasingly driving the global IVF devices and consumables market trends, satisfying the increased need for effective fertility solutions.

North America holds the largest share in the global IVF devices and consumables market, leading the health care structure, fertility treatment awareness, and access to advanced IVF technologies. The United States is prominent in this region, holding wide ranges of fertility clinics, coupled with relentless investments in research and development for the advancement of the sector.